AbbVie Inc

ABBV is in a Stage 2 advance displaying higher highs and higher lows with rising EMAs, indicating sustained bullish momentum. Medium- and long-term directional biases are bullish given the active continuation pattern and strong moving-average alignment. Short-term pullback into the 20/50 EMA zone is constructive and offers a favorable entry now on a rebound from dynamic support.

• ↑Q2 2026 net revenues of $17B (+10.2% YoY) fueled by Skyrizi and Renvoke.
• ↑Adjusted EPS of $3.65 beat guidance; full-year revenue guide raised to $67.6B.
• ↓Humira revenues set to decline over $4B in 2026 due to biosimilars.